Compare DDI & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDI | SENS |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.0M | 496.0M |
| IPO Year | 2020 | 2014 |
| Metric | DDI | SENS |
|---|---|---|
| Price | $12.75 | $8.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $19.00 | $18.38 |
| AVG Volume (30 Days) | 115.0K | ★ 676.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | $6.65 | $74.15 |
| Revenue Next Year | $2.64 | $58.60 |
| P/E Ratio | $4.31 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $8.10 | $0.41 |
| 52 Week High | $13.28 | $10.15 |
| Indicator | DDI | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 56.28 |
| Support Level | $12.60 | $5.13 |
| Resistance Level | $13.28 | $9.99 |
| Average True Range (ATR) | 0.29 | 0.52 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 23.53 | 11.10 |
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States, while it also has its presence in Canada, Germany, United Kingdom, and International-Other. The games offered by the company are: Doubledown Casion, Doubledown Fortknox, and Doubledown Classic Slots.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.